Ex Vivo Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumors 公告 2024-12-17 17:15:49 Written By Kym Kilbourne Title: Ex Vivo Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumors ClinicalTrials.gov ID: NCT06246630 Sponsor: Ruijin Hospital Provider of Information: Jin Jiabin, Ruijin Hospital (Responsible Party) Last Update Posted: 2024-05-16 Study Overview Brief Summary The purpose of this study is to explore whether chemotherapy and targeted treatment regimens guided by organoid drug sensitivity testing can improve the prognosis of unresectable locally advanced and metastatic pancreatic neuroendocrine tumors (p-NET). Additionally, this study will assess the consistency between drug sensitivity test results from organoid biopsies and patient treatment responses. Detailed Description Twenty patients with unresectable locally advanced and metastatic pancreatic neuroendocrine tumors (p-NET) who should receive palliative treatment will be included in this study. Baseline information of enrolled patients, including medical history, physical examination records, and clinical examination records, will be collected. Tumor materials from these patients will be obtained from pancreatic endoscopic biopsies or surgical resections. Patient-derived organoids (PDO) will be established and cultured from p-NET tumor specimens. Subsequently, PDOs will be treated with chemotherapy drugs and targeted treatment regimens for p-NET. The size and growth of organoids will be monitored before and after treatment, and dose-response curves will be generated. For the assessment of patient clinical outcomes, treatment responses will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) through biomedical imaging. The consistency between treatment responses in PDO models and patient clinical outcomes will be assessed through correlation analysis. Official Title A Prospective Exploratory Study to Evaluate the Effectiveness of Treatment Regimens for Locally Advanced/Metastatic Unresectable Pancreatic Neuroendocrine Tumors (PNET) Guided by Ex Vivo Tumor Drug Sensitivity Test Organoids Condition Advanced Pancreatic Neuroendocrine Tumor Intervention/Treatment Other: Chemotherapy and targeted therapy guided by organoid drug sensitivity testing Other Study ID Numbers Ruijin 20231007060328844 Contact and Location Information Study Contact Name: Jin Jiabin, PhD Phone: 008618101870031 Email: jjb11501@rjh.com.cn Study Link: https://clinicaltrials.gov/study/NCT06246630?term=organoid%20Guided&aggFilters=status:rec&rank=6 Kym Kilbourne
Ex Vivo Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumors 公告 2024-12-17 17:15:49 Written By Kym Kilbourne Title: Ex Vivo Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumors ClinicalTrials.gov ID: NCT06246630 Sponsor: Ruijin Hospital Provider of Information: Jin Jiabin, Ruijin Hospital (Responsible Party) Last Update Posted: 2024-05-16 Study Overview Brief Summary The purpose of this study is to explore whether chemotherapy and targeted treatment regimens guided by organoid drug sensitivity testing can improve the prognosis of unresectable locally advanced and metastatic pancreatic neuroendocrine tumors (p-NET). Additionally, this study will assess the consistency between drug sensitivity test results from organoid biopsies and patient treatment responses. Detailed Description Twenty patients with unresectable locally advanced and metastatic pancreatic neuroendocrine tumors (p-NET) who should receive palliative treatment will be included in this study. Baseline information of enrolled patients, including medical history, physical examination records, and clinical examination records, will be collected. Tumor materials from these patients will be obtained from pancreatic endoscopic biopsies or surgical resections. Patient-derived organoids (PDO) will be established and cultured from p-NET tumor specimens. Subsequently, PDOs will be treated with chemotherapy drugs and targeted treatment regimens for p-NET. The size and growth of organoids will be monitored before and after treatment, and dose-response curves will be generated. For the assessment of patient clinical outcomes, treatment responses will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) through biomedical imaging. The consistency between treatment responses in PDO models and patient clinical outcomes will be assessed through correlation analysis. Official Title A Prospective Exploratory Study to Evaluate the Effectiveness of Treatment Regimens for Locally Advanced/Metastatic Unresectable Pancreatic Neuroendocrine Tumors (PNET) Guided by Ex Vivo Tumor Drug Sensitivity Test Organoids Condition Advanced Pancreatic Neuroendocrine Tumor Intervention/Treatment Other: Chemotherapy and targeted therapy guided by organoid drug sensitivity testing Other Study ID Numbers Ruijin 20231007060328844 Contact and Location Information Study Contact Name: Jin Jiabin, PhD Phone: 008618101870031 Email: jjb11501@rjh.com.cn Study Link: https://clinicaltrials.gov/study/NCT06246630?term=organoid%20Guided&aggFilters=status:rec&rank=6 Kym Kilbourne
